Main description:

This volume presents a detailed survey of cancers. This volume was written by of various methodologies related to diag- 94 oncologists representing 13 countries. nosis, therapy, and prognosis of ovar- Their practical experience highlights their ian cancer, renal cancer, urinary bladder writings, which should build and further cancer, and cervical uterine cancer, while the endeavors of the readers in this imp- the already published Volumes 1-5 detail tant area of disease. The text of each c- similar aspects of breast, lung, prostate, cer type is divided into subheadings for liver, gastrointestinal, colorectal, and bil- the convenience of the readers. It is my iary tract carcinomas. hope that the current volume will join the It is well established that cancer is the preceding volumes of this series for assi- deadliest of human diseases. The follow- ing in the more complete understanding ing estimated global incidence of seven of globally relevant cancer syndromes. types of cancers discussed in this volume There exists a tremendous, urgent demand indicated the seriousness of this malig- by the public on the scientific community nancy. to address cancer prevention, diagnosis, treatment, and hopefully cures. Cervical uterine cancer 493,342 I am grateful to the contributors for their Urinary bladder cancer 357,000 promptness accepting my suggestions. I respect their dedication and diligent work Leukemia 300,522 in sharing their invaluable knowledge with Renal cancer 208,480 the public through this series.

Contents:

PART I. OVARIAN CANCER Diagnosis 1. IDENTIFICATION OF BIOMARKERS FOR CLEAR CELL OVARIAN ADENOCARCINOMA; Samuel C. Mok, Michael P. Stanley, Hiroshi Tsuda, and Michael J. Birrer INTRODUCTION
GENETIC ALTERATIONS IN CLEAR CELL OVARIAN CANCER
CLEAR CELL OVARIAN CANCER HAS DISTINCT
TRANSCRIPTION PROFILES
DIFFERENTIAL GENE EXPRESSION IN CLEAR CELL
ADENOCARCINOMA OF DIFFERENT ORGANS
REFERENCES 2. OVARIAN CARCINOMA: DIAGNOSTIC IMMUNOHISTOCHEMISTRY OF MUCIN 4 (MUC4); Moorthy P. Ponnusamy, Ajay P. Singh, Subodh M. Lele, and Surinder K. Batra INTRODUCTION
HISTOPATHOLOGY OF OVARIAN CANCER
STAGES AND PROGNOSIS OF OVARIAN CANCER
BIOMARKERS AND SCREENING OF OVARIAN CANCER
ABERRANT MUCIN EXPRESSION IN OVARIAN CANCER
MUCIN 4: Structure and Biology
MUCIN 4 in Ovarian Cancer
METHODOLOGY FOR MUCIN4 IMMUNOHISTOCHEMISTRY
Tissue Sectioning
Immunolabeling
Assessment of MUC4 Staining
REFERENCES 3. DISTINGUISHING BENIGN FROM MALIGNANT COMPLEX ADNEXAL MASSES IN OVARIAN CANCER: TWO- DIMENSIONAL POWER-DOPPLER IMAGING; Juan Luis Alcazar INTRODUCTION
PATIENTS AND METHODS
RESULTS
DISCUSSION
CONCLUSION
REFERENCES 4. SUBGROUPS OF OVARIAN CARCINOMA: IDENTIFICATION USING DIFFERENTIAL GENE EXPRESSION; Kristin L.M. Boylan, Keith M. Skubitz, and Amy P.N. Skubitz INTRODUCTION
OVARIAN CANCER HETEROGENEITY
SELECTION OF SAMPLES FOR GENE MICROARRAY ANALYSIS
CONTAMINATION OF GENE EXPRESSION PROFILES BY OTHER
CELLS IN TISSUES
NUMBER OF SAMPLES TO ANALYZE FOR GENE PROFILING
IMPORTANCE OF PATHOLOGICAL QUALITY CONTROL
CLINICAL CORRELATIONS
GENE MICROARRAY PLATFORMS
RNA ISOLATION FOR GENERATING GENE EXPRESSION DATA
ANAYSIS OF GENE MICROARRAY DATA
NEED FOR SECONDARY VALIDATION OF DATA
GOALS FOR GENE MICROARRAY ANAYSIS
GENE EXPRESSION ANALYSIS USED TO DETERMINE OVARIAN
CANCER SUBGROUPS
GENE EXPRESSION ANALYSIS USED TO COMPARE DIFFERENT
STAGES OR GRADES OF OVARIAN CANCER
GENE EXPRESSION PROFILES BASED ON METASTASIS
CORRELATION OF GENE EXPRESSION PROFILES TO
CHEMOTHERAPEUTIC RESPONSE
CORRELATION OF GENE EXPRESSION PROFILES TO SURGICAL DEBULKING
CORRELATION OF GENE EXPRESSION PROFILES TO PATIENTS' SURVIVAL
REFERENCES 5. SERTOLIFORM ENDOMETRIOID CARCINOMA OF THE OVARY: DIAGNOSIS AND PROGNOSIS; Monalisa Sur and Dean Daya INTRODUCTION
DIAGNOSIS
Clinical Features
Gross Findings
Microscopic Findings
DIFFERENTIAL DIAGNOSIS
IMMUNOHISTOCHEMISTRY
Cytokeratins
Epithelial Membrane Antigen
Inhibin
Calretinin
Neural Cell Adhesion Molecule
Estrogen and Progesterone Receptors
Other Markers
PROGNOSIS
REFERENCES Prognosis 6. ROLE OF MUC16 (CA125) IN THE PATHOGENESIS OF EPITHELIAL OVARIAN CANCER; Jennifer A. Arens Gubbels, Joseph P. Connor, and Manish S. Patankar INTRODUCTION
CA125 and MUC16
MUC16 in Epithelial Ovarian Cancer
MESOTHELIN AND MUC16 BINDING: A MODEL FOR METASTASIS
Mesothelin
Mesothelin and MUC16 Binding
Kinetics of Mesothelin-MUC16 Binding
Mesothelin Binds to N-Linked Oligosaccharides Present on MUC16
MUC16 BINDING TO NATURAL KILLER CELLS: IMMUNOSUPPRESSIVE EFFECTS
A Phenotypic Shift
NK Cell Differentiation
Tumor Cell Layers of Protection
REFERENCES 7. CLEAR CELL CARCINOMA OF THE OVARY: PROGNOSIS USING CYTOREDUCTIVE SURGERY; Masashi Takano, Naoki Sasaki, and Toru Sugiyama INTRODUCTION
CLINICAL CHARACTERISTICS
MOLECULAR CHARACTERISTICS
CLINICAL OUTCOME
Resistance to